期刊文献+

冠状动脉旁路移植术前替格瑞洛停用时间对围术期出血风险的影响 被引量:3

Effect of hemorrhagic risk of ticagrelor discontinuation time before perioperative period on coronary artery bypass grafting
下载PDF
导出
摘要 目的探讨冠状动脉旁路移植术(CABG)前停用替格瑞洛的时间对围术期出血风险的影响。方法纳入2013年7月至2017年12月行CABG术前服用替格瑞洛的冠心病患者188例,根据术前替格瑞洛停药时间分为≥5d组(126例)和<5d组(62例)。比较两组基线资料及围术期严重出血资料,单因素和多因素logistic回归分析严重出血的危险因素。主要终点为围术期严重出血。结果31例(16.5%)患者出现严重出血,其中≥5d组有15例(11.9%),<5d组有16例(25.8%)。两组的年龄、性别、术前红细胞压积等基线资料无明显差异(均为P>0.05)。多因素logistic回归分析显示,急性心肌梗死史(OR=5.49,95%CI:1.25~24.17)和替格瑞洛停药<5d(OR=2.50,95%CI:1.13~5.56)是严重出血的危险因素。结论替格瑞洛术前停药时间小于5d可增加CABG患者围术期严重出血风险。 Objective To evaluate the effect of hemorrhagic risk of time of discontinuation of ticagrelor before coronary artery bypass grafting (CABG) on perioperative period. Methods A total of 188 patients on ticagrelor and scheduled for CABG enrolled into this study from July 2013 and December 2017. The patients were divided into the ≥5d (n=126) group and the <5d group (n =62) according to ticagrelor discontinuation time before CABG operation. Baseline characteristics and hemorrhagic data were compared between two groups. Univariate and multivariate logistic regression analyses were performed to investigate the risk factors of major bleeding. The primary endpoint was major bleeding. Results 31 patients had major bleeding (16.5%). Among those patients, 15 cases were in the ≥5 d group (11.9%) and 16 in the <5 d group (25.8%). Baseline characteristics, such as age, male ratio, hematocrit, were similar between the two groups (all P >0.05). Multivariate logistic regression analysis showed that the acute myocardial infarction (OR=5.49, 95%CI: 1.25-24.17) and discontinuation less than 5 d of ticagrelor (OR= 2.50, 95%CI: 1.13-5.56) were risk factors for major bleeding. Conclusions Discontinuation of ticagrelor less than 5 days before CABG may increase the risk of severe perioperative bleeding in CABG patients.
作者 王佳鑫 刘巍 周玉杰 席子惟 Wang Jiaxin;Liu Wei;Zhou Yujie;Xi Ziwei(School of Public Health, Capital Medical University, Beijing 100069, China;Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China)
出处 《中国心血管杂志》 2019年第3期227-230,共4页 Chinese Journal of Cardiovascular Medicine
关键词 冠状动脉旁路移植术 替格瑞洛 围术期 出血 停药时间 Coronary artery bypass Ticagrelor Perioperative period Hemorrhage Time of discontinuation
  • 相关文献

参考文献2

二级参考文献26

  • 1Cattaneo M.ADP receptors anatagonists[M]//Michelson AD,ed.Platelets San Diego,Calif Academic Press,2006:1127-1144.
  • 2O′Donoghue ML,Braunwald E,Antman EM,et al.Pharmacodynamic effect and clinicl efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials[J].Lancet,2009,374(9694):989-997.
  • 3Farid NA,Payne CD,Small DS,et al.Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently[J].Clin Pharmacol Ther,2007,81(5):735-741.
  • 4Wiviott SD,Braunwald E,Angiolillo DJ,et al.For the TRITON-TIMI38 Investigators,Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Thrombolysis Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis in Myocardial Infarction 38[J].Circulation,2008,118(16):1626-1636.
  • 5Montalescot G,Wiviott SD,Braunwald E,et al.For the TRITON-TIMI38 investigators,prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction(TRITON-TIMI38);double-blind,randomised controlled trial[J].Lancet,2009,373(9665):723-731.
  • 6Murphy S,Antman EM,Wiviott SD,et al.For the TRITON-TIMI38 investigators,reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial[J].Eur Heart J,2008,29(20):2473-2479.
  • 7Wiviott SD,Braunwald E,McCabe CH,et al.For the TRITON-TIMI38 Investigators,Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.
  • 8Marteau F,Le Poul E,Communi D,et al.Pharmacological characterization of the human P2Y13 receptor[J].Mol Pharmacol,2003,64(1):104-112.
  • 9Srinivasan S,Mir F,Huang JS,et al.The P2Y12 antagonists,2-methylthioadenosine 5-monophosphate triethylammonium salt and cangrelor (ARC69931MX),can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels[J].J Biol Chem,2009,284(24):16108-16117.
  • 10Van Giezen JJJ,Humphries RG.Preclinical and clinical studieds with selective reversible direct P2Y12 antagonists[J].Semin Tromb Hemost,2005,31(2):195-204.

共引文献7

同被引文献22

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部